Turkey Medical Devices Market Report 2026: TİTCK Regulation, SGK SUT Reimbursement, and Medical Tourism Intelligence

The Turkish medical devices market is estimated at USD 3.0–4.0 billion in 2026, making it the largest medical device market in the MENA extended region outside the GCC and Egypt, and one of the fastest-growing in Europe-MENA. Turkey has approximately 1,500 hospitals — over 500 of which are private — serving both a domestic population of 87 million and approximately 1.5 million medical tourists annually. The private hospital sector (Medical Park, Medicana, Florence Nightingale, Anadolu Medical) is among the most dynamic device procurement channels in the region, adopting novel technologies at competitive price points.

TİTCK (Türkiye İlaç ve Tıbbi Cihaz Kurumu — Turkish Medicines and Medical Devices Agency) regulates medical devices in Turkey. Turkey has adopted the EU MDR 2017/745 framework, requiring CE marking for devices on the Turkish market — CE marking from an EU Notified Body is accepted for Turkish registration. TİTCK maintains the ÜTS (Ürün Takip Sistemi — Product Tracking System) database where all medical devices distributed in Turkey must be registered. The ÜTS unique device identifier (UDI-like) system tracks device distribution and post-market surveillance. TİTCK conducts post-market vigilance, manages adverse event reporting (KDMR system), and coordinates with EU competent authorities through bilateral agreements.

SGK (Social Security Institution) reimburses medical devices through the SUT (Sağlık Uygulama Tebliği — Health Implementation Circular), which lists eligible device categories with reimbursement prices and clinical criteria. SGK uses a reference pricing mechanism for devices — reimbursement prices are set relative to EU or international reference markets, with exchange rate adjustments. For hospital-used devices covered within SGK procedure payments (DRG-equivalent SUT procedure codes), devices are bundled within the procedure tariff. High-cost implants and specialised devices have separate SUT listing procedures. Private hospital patients with supplemental insurance (BES accounts, private health insurance) can access devices above the SGK tariff with top-up payments.

The fastest-growing Turkish medical device segments are: robotic surgery (Private hospital groups Medical Park and Medicana have expanded da Vinci and Mako installations; robotic surgery is a medical tourism draw); AI-enhanced diagnostics (Turkey is among the leading emerging markets for AI diagnostic imaging implementation); cosmetic and aesthetic devices (Turkey is the world's top destination for hair transplantation and a major aesthetic medicine tourism hub — aesthetic laser, thread lift, and body contouring device demand is significant); orthopaedics and trauma (high procedural volume at private hospitals serving medical tourists from MENA and EU); and cardiovascular devices (structural heart, cardiac electrophysiology growing at private and university hospitals).

Turkey attracted approximately 1.5 million medical tourists in 2025, generating approximately USD 2.5 billion in medical tourism revenue. Key medical tourism specialties include: hair transplantation (Turkey is the global leader — 500,000+ procedures annually), dental (implants, veneers), aesthetic surgery, ophthalmology (LASIK, cataract), oncology, and cardiac surgery. Private hospitals serving the medical tourism segment — particularly those in Istanbul — procure premium devices to attract international patients comparing quality with EU or GCC alternatives. The medical tourism dynamic means premium device acceptance at private Turkish hospitals significantly exceeds what the domestic patient economy alone would justify, creating a commercially attractive channel for international device manufacturers.

BioNixus supports Turkish medical device manufacturers in entering GCC and MENA markets. Turkish medtech companies — particularly in dental devices, ophthalmology, and aesthetic medicine — have growing GCC market presence. Turkey's CE marking adoption creates regulatory evidence directly usable for GCC registrations (SFDA accepts CE; MOHAP accepts CE). BioNixus provides SFDA, MOHAP/DHA/DOH, HMC, and GCC-wide regulatory pathway intelligence; hospital and clinic procurement data; distributor network mapping; and primary research with clinical specialists across the GCC. The Turkey-GCC commercial corridor is strategically significant — Turkey and the GCC share strong trade and cultural relationships that support medical device commercial development.